Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy.
Tomás PascualAranzazu Fernandez-MartinezMaki TaniokaMaria Vittoria DieciSonia PernasJoaquin GavilaValentina GuarnieriJavier CortesPatricia VillagrasaNúria ChicMaría Jesús Vidal LosadaBarbara AdamoMontserrat MuñozGaia GriguoloAntonio LlombartPierFranco ConteMafalda OliveiraBenedetta ConteLaia ParéPatricia GalvanLisa Anne CareyCharles M PerouAleix PratPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
In HER2+/HR+ breast cancer, CES is useful for predicting chemo-endocrine sensitivity and provides additional prognostication beyond intrinsic subtype and clinicopathologic characteristics.